SPOTLIGHT: Hollis-Eden skyrockets on preclinical cancer data

At the 2007 ASCO Breast Cancer Symposium, Hollis-Eden reported impressive data for HE3235, a preclinical candidate for breast cancer. HE3235 significantly inhibited the incidence of new tumors and stopped the growth of existing tumors in a preclinical model of breast cancer. The company's stock shot up 30 percent on the news. Last week, Hollis-Eden was featured [1] in FierceBiotech's weekly series [2] on emerging drug developers. Release [3]